Greater Zurich Area’s Post

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/4MBLGy. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/rtMvna. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/lwt076. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/fzygaI. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/pIvZmK. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

📢 ICYMI in The Globe and Mail: the Metro Vancouver region is positioning itself as a global pharma capital.   Recently, the Globe and Mail published an article on the Metro Vancouver region's "biotech boom". Key takeaways from the article: 👩🔬 Metro Vancouver is already Canada’s fastest-growing biotech centre, with 8,000 jobs added over the past 10 years, up to nearly 20,000 🧪 Companies located here, such as AbCellera, are leading the charge to establish the region as a major player in the US$1.5-trillion pharmaceutical industry, with both top-notch medical researchers and the capacity for commercialization 🔬 The region benefits from a tight-knit group of universities, agencies, institutes, associations, funders, academics and founders working together to build startups and a supportive ecosystem, – including funding to expand training, and capacity to conduct drug trials and manufacture locally   As noted in our 2023 report on the Life Sciences industry in the region, Metro Vancouver has the potential to lead not only the country but also the world in breakthrough biotech. As Brian Bloom says in the article, “When it comes to the true discovery biotech companies that can turn into integrated biopharmas, nothing comes close to Vancouver.”   📖 Read our 2023 research on the industry: https://lnkd.in/e5nS98SG 📰 Check out the full Globe and Mail article for more: https://lnkd.in/e93P7qxm

The BioVerse EP006 - #Physician Scientists' Checklist for Successful #Global #Clinical Development has concluded with a highly engaging and productive discussion. Led by a panel of experienced pharmaceutical industry veterans, including Axel Hoos, David Weinstock, Francisco Leon, and Li Yan, the session delved into the insights behind their #trackrecord of #approved drugs. They also shared the secrets behind some turnaround stories and offered advice, particularly to #emerging #biotechs, including those in #China, aspiring to develop #innovativemedicines for the #globalmarket and patients worldwide. 🌟 Two pivotal #takeaways emerged: the importance of following the #science and cultivating trusted relationships. With real-world examples (#realworldevidence #realworlddata) provided by the panelists for immediate illustration, the objective of #empowering the #community to advance with increased confidence was successfully achieved. Ipilimumab was highlighted to underscore the critical role of following the #science in steering #clinicaldevelopment programs. This involves introducing #novelmechanisms and #paradigms to #investigators, #regulators, and #patients. Ensuring alignment and #stakeholder #endorsement relies heavily on the "follow the science" principle, extending to areas such as cross-therapeutic #repurposing, learning from "failed" trials, and reverse translation. The significance of building and maintaining #trusted #relationships was highlighted for the smooth #execution of clinical development strategies, effective partnerships with various parties, and successful #business #collaborations. The panelists provided vivid examples to illustrate the value of fostering strong relationships. As closing remarks, the panelists also offered valuable advice to #Chinese biotech firms: 1️⃣ Biotechs should establish a global clinical development plan from the outset, rather than altering it as an afterthought. 2️⃣ Emphasis was placed on the critical importance of high-quality #CMC, particularly for clinical-stage #assets. 3️⃣ The recurring emphasis on cultivating strong and quality relationships was mentioned once more. Revisit the episode by clicking here: https://lnkd.in/erZVwM9y. Also, welcome to join the upcoming IO360 at #NYC (https://io360summit.com/) with InScienceWeTrust Community on Feb 27-29 and @SAPA-GP annual conference at #GreaterPhiladelphia (https://qrco.de/benTPs) on March 8-9!

Great achievements from our PhD candidates! Three of PhD students supervised by Dr. Himanshu Kaul have been accepted to the Conception X Accelerator programme. They are Bo Tian, Mael Derjean (Respiratory Sciences), and Mahesh Kumar Ola. Conception X will provide them training to commercialise the 3 different technologies they are developing in the Kaul Lab. Bo is developing software to help industries undertake reconfiguration rapidly and economically, Mael is developing a protocol to create ‘lung organoids’ that will help pharmaceutical companies understand drug pharmacodynamics, and Mahesh is engineering a multiscale virtual patient that will enable efficacious clinical decision-making. #engineering #phd #commercialisation

𝗥𝗼𝗰𝗵𝗲 𝗮𝗻𝗱 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀: 𝗕𝗮𝘀𝗲𝗹'𝘀 𝗥&𝗜 𝗽𝗼𝘄𝗲𝗿𝗵𝗼𝘂𝘀𝗲𝘀 Both research and innovation (R&I) are key drivers of a successful drug pipeline. With this in mind, we at the CIEB Universität Basel analyzed the quality of large pharma companies' R&I activities. Here are our key findings: - Basel-based 𝐑𝐨𝐜𝐡𝐞 is very strong in R&I, as evidenced by a much higher than average number of citations per scientific paper and patent. Basel-based 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 is also above average on both counts. - 𝐀𝐦𝐠𝐞𝐧, 𝐆𝐢𝐥𝐞𝐚𝐝 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬, 𝐀𝐬𝐭𝐫𝐚 𝐙𝐞𝐧𝐞𝐜𝐚, 𝐚𝐧𝐝 𝐁𝐫𝐢𝐬𝐭𝐨𝐥 𝐌𝐲𝐞𝐫𝐬 𝐒𝐪𝐮𝐢𝐛𝐛 also have both highly cited scientific papers and patents. 𝐀𝐦𝐠𝐞𝐧 in particular has received many citations for its patents. - 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤, 𝐏𝐟𝐢𝐳𝐞𝐫, 𝐁𝐚𝐲𝐞𝐫, 𝐚𝐧𝐝 𝐆𝐥𝐚𝐱𝐨 𝐒𝐦𝐢𝐭𝐡 𝐊𝐥𝐢𝐧𝐞 have highly cited scientific papers but not as many highly cited patents. -> In summary, our analysis confirms that 𝐑𝐨𝐜𝐡𝐞 and 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 are among the leaders in producing highly cited and influential R&I. These results point to a positive future for Basel in drug development and healthcare innovation.   Notes: Data include company affiliations. For example, Genentech is assigned to Roche. We used all USPTO patents and scientific papers from the Scopus database attributed to the pharmaceutical field between 2013 and 2022. For patents, we used docdb family citations, and for papers, we weighted citations by author (as papers often contain a larger number of authors from different institutions). #BaselInnovation #pharma #research #innovation Christian Rutzer Till Schmidlin Valentina Francia, PhD Interpharma

🌟 Exciting News from Nano4Rare! 🌟 🌍 We are thrilled to announce the Nano4Rare EIC Transition project started on 1st November 2023 and led by the INSTITUT DE CIÈNCIA DE MATERIALS DE BARCELONA (ICMAB-CSIC). 🌐 About Nano4Rare: Nano4Rare is a European project financed by the European Innovation Council and SMEs Executive Agency (EISMEA). It has a singular focus: to bring a new #nanopharmaceutical product for the treatment of Fabry disease (named as nanoGLA) to First-in Human clinical trials. #NanoGLA is patent protected and was designated as Orphan Medicinal Product by the European Medicines Agency in 2021, two important milestones with high implications for the translation of the new therapeutic product from bench to bedside. Nano4Rare project is expected to mature the development of this innovative nanopharmaceutical product by completing the GLP preclinical phase and regulatory approval. To achieve this objective, we will account with the collaboration of NANOMOL TECHNOLOGIES, LeanBioPro, and MyBiotech GmbH, which are partners of its linked project 953110 PHOENIX OITB that will cover the Chemistry, Manufacturing, and Controls (CMC) development. Additionally, in the frame of Nano4Rare, an appropriate business strategy will be implemented to ensure the financing of further clinical trials and the arrival to the market. 🤝 Connect with Us: Follow Nano4Rare on LinkedIn for regular updates, insights, and opportunities to be part of this ground-breaking initiative. Together, we can make a difference! #Nano4Rare #RareDiseases #Innovation #Healthcare #ClinicalTrials #ICMAB #CSIC INSTITUT DE CIÈNCIA DE MATERIALS DE BARCELONA (ICMAB-CSIC) CSIC CSIC Innovación Centro de Investigación Biomédica en Red CIBER NANBIOSIS – ICTS